Azilsartan(AZL), a poorly soluble drug, was considered to be fit for nanocrystals to improve its solubility. Our study intended to prepare AZL nanocrystals by means of bead milling method. Eight stabilizers or their b...Azilsartan(AZL), a poorly soluble drug, was considered to be fit for nanocrystals to improve its solubility. Our study intended to prepare AZL nanocrystals by means of bead milling method. Eight stabilizers or their binary combination and the milling time were set to be variable factors to optimize AZL nanosuspension formulation, and six types of freezedrying supports were investigated to reduce the aggregation of particles during the solidification. AZL nanocrystals with or without sodium deoxycholate(NaDC) as combined stabilizer with Poloxamer 188(F68) were prepared owning mean particle sizes of about 300 nm and 460 nm. During the screening processes, the formulation containing NaDC showed a smaller particle size and better stability during lyophilization. The irregular shape and crystal form changing in AZL nanocrystals were discovered by various characterizations. And with physical mixture as reference, nanocrystals showed its improvement about in-vitro dissolution and in-vivo bioavailability. In conclusion, the nanocrystals of AZL could be prepared well in our study. Additionally, our results suggested that NaDC was an appreciated excipient on the nanocrystals platform, which can exhibit the abilities of size-reduction and stabilitymaintaining on freeze-drying.展开更多
The purpose of the study is to develop an ultra performance liquid chromatographytandem mass spectrometry(UPLCeMS/MS)to determinate the concentration of azilsartan in the dog plasma.After precipitated by methanol,the ...The purpose of the study is to develop an ultra performance liquid chromatographytandem mass spectrometry(UPLCeMS/MS)to determinate the concentration of azilsartan in the dog plasma.After precipitated by methanol,the plasma sample containing azilsartan and diazepam(internal standard,IS)was determined by UPLCeMS/MS.The mobile phase consisted of acetonitrile-water was pumped at a flow rate of 0.3 ml/min in gradient elution.Kinetex 2.6 m XB-C18 column(502.1 mm,100Å;Phenomenex,USA)were used for LC separations.The column temperature was 30℃ and the injection volume was 5 ml.The electrospray ionization(ESI)and multiple reaction monitoring(MRM)were applied at the transitions of m/z 457/279(azilsartan)and m/z 285/193(diazepam),respectively.The developed method was identified a good linearity over a concentration range of 2.5e5000 ng/ml.The lower limit of quantitation(LLOQ)was 2.5 ng/ml.The intraday and inter-day precision(relative standard deviation,RSD%)were less than 10%and accuracy(relative error,RE%)was less than 5%at three quality control levels.The extraction recovery of azilsartan at three quality control levels were 82.41±0.68%,98.66±11.00%,102.43±0.82%.And the recovery for IS(100 ng/ml)was 91.75±0.54%.A validated UPLCeMS/MS method was firstly developed for the quantification of azilsartan in dog plasma and it was applied to the pharmacokinetics study.展开更多
Azilsartan (2-ethoxy-1-([2’-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl)-1H-benzimidazole-7-carboxylic acid) is a new angiotensin II receptor antagonist used in the treatment of hypertension. This pa...Azilsartan (2-ethoxy-1-([2’-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl)-1H-benzimidazole-7-carboxylic acid) is a new angiotensin II receptor antagonist used in the treatment of hypertension. This paper describes the preparation of type I crystal and its single crystal diffraction data, the comparison of the powder diffraction data for both type I and II crystals as well as their stability and solubility in methanol.展开更多
Tremendous efforts have been devoted to the enhancement of drug solubility using nanotechnologies, but few of them are capable to produce drug particles with sizes less than a few nanometers. This challenge has been a...Tremendous efforts have been devoted to the enhancement of drug solubility using nanotechnologies, but few of them are capable to produce drug particles with sizes less than a few nanometers. This challenge has been addressed here by using biocompatible versatile γ-cyclodextrin(γ-CD) metal-organic framework(CD-MOF) large molecular cages in which azilsartan(AZL) was successfully confined producing clusters in the nanometer range. This strategy allowed to improve the bioavailability of AZL in Sprague–Dawley rats by 9.7-fold after loading into CD-MOF. The apparent solubility of AZL/CD-MOF was enhanced by 340-fold when compared to the pure drug. Based on molecular modeling, a dual molecular mechanism of nanoclusterization and complexation of AZL inside the CD-MOF cages was proposed, which was confirmed by small angle X-ray scattering(SAXS) and synchrotron radiation-Fourier transform infrared spectroscopy(SR-FTIR) techniques. In a typical cage-like unit of CD-MOF, three molecules of AZL were included by the γ-CD pairs, whilst other three AZL molecules formed a nanocluster inside the 1.7 nm sized cavity surrounded by six γ-CDs. This research demonstrates a dual molecular mechanism of complexation and nanoclusterization in CD-MOF leading to significant improvement in the bioavailability of insoluble drugs.展开更多
基金financially supported by Science research project of Department of Education Liaoning Province(No.L2013390)
文摘Azilsartan(AZL), a poorly soluble drug, was considered to be fit for nanocrystals to improve its solubility. Our study intended to prepare AZL nanocrystals by means of bead milling method. Eight stabilizers or their binary combination and the milling time were set to be variable factors to optimize AZL nanosuspension formulation, and six types of freezedrying supports were investigated to reduce the aggregation of particles during the solidification. AZL nanocrystals with or without sodium deoxycholate(NaDC) as combined stabilizer with Poloxamer 188(F68) were prepared owning mean particle sizes of about 300 nm and 460 nm. During the screening processes, the formulation containing NaDC showed a smaller particle size and better stability during lyophilization. The irregular shape and crystal form changing in AZL nanocrystals were discovered by various characterizations. And with physical mixture as reference, nanocrystals showed its improvement about in-vitro dissolution and in-vivo bioavailability. In conclusion, the nanocrystals of AZL could be prepared well in our study. Additionally, our results suggested that NaDC was an appreciated excipient on the nanocrystals platform, which can exhibit the abilities of size-reduction and stabilitymaintaining on freeze-drying.
文摘The purpose of the study is to develop an ultra performance liquid chromatographytandem mass spectrometry(UPLCeMS/MS)to determinate the concentration of azilsartan in the dog plasma.After precipitated by methanol,the plasma sample containing azilsartan and diazepam(internal standard,IS)was determined by UPLCeMS/MS.The mobile phase consisted of acetonitrile-water was pumped at a flow rate of 0.3 ml/min in gradient elution.Kinetex 2.6 m XB-C18 column(502.1 mm,100Å;Phenomenex,USA)were used for LC separations.The column temperature was 30℃ and the injection volume was 5 ml.The electrospray ionization(ESI)and multiple reaction monitoring(MRM)were applied at the transitions of m/z 457/279(azilsartan)and m/z 285/193(diazepam),respectively.The developed method was identified a good linearity over a concentration range of 2.5e5000 ng/ml.The lower limit of quantitation(LLOQ)was 2.5 ng/ml.The intraday and inter-day precision(relative standard deviation,RSD%)were less than 10%and accuracy(relative error,RE%)was less than 5%at three quality control levels.The extraction recovery of azilsartan at three quality control levels were 82.41±0.68%,98.66±11.00%,102.43±0.82%.And the recovery for IS(100 ng/ml)was 91.75±0.54%.A validated UPLCeMS/MS method was firstly developed for the quantification of azilsartan in dog plasma and it was applied to the pharmacokinetics study.
文摘Azilsartan (2-ethoxy-1-([2’-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl)-1H-benzimidazole-7-carboxylic acid) is a new angiotensin II receptor antagonist used in the treatment of hypertension. This paper describes the preparation of type I crystal and its single crystal diffraction data, the comparison of the powder diffraction data for both type I and II crystals as well as their stability and solubility in methanol.
基金financial support from the Project funded by the National Science and Technology Major Projects for the Major New Drugs Innovation and Development (2018ZX09721002-009, China)Strategic Priority Research Program of Chinese Academy of Sciences (XDA12050307)+1 种基金National Natural Science Foundation of China (81430087)China Postdoctoral Science Foundation (2017M610284)
文摘Tremendous efforts have been devoted to the enhancement of drug solubility using nanotechnologies, but few of them are capable to produce drug particles with sizes less than a few nanometers. This challenge has been addressed here by using biocompatible versatile γ-cyclodextrin(γ-CD) metal-organic framework(CD-MOF) large molecular cages in which azilsartan(AZL) was successfully confined producing clusters in the nanometer range. This strategy allowed to improve the bioavailability of AZL in Sprague–Dawley rats by 9.7-fold after loading into CD-MOF. The apparent solubility of AZL/CD-MOF was enhanced by 340-fold when compared to the pure drug. Based on molecular modeling, a dual molecular mechanism of nanoclusterization and complexation of AZL inside the CD-MOF cages was proposed, which was confirmed by small angle X-ray scattering(SAXS) and synchrotron radiation-Fourier transform infrared spectroscopy(SR-FTIR) techniques. In a typical cage-like unit of CD-MOF, three molecules of AZL were included by the γ-CD pairs, whilst other three AZL molecules formed a nanocluster inside the 1.7 nm sized cavity surrounded by six γ-CDs. This research demonstrates a dual molecular mechanism of complexation and nanoclusterization in CD-MOF leading to significant improvement in the bioavailability of insoluble drugs.
